Can a 2-week drug boost scan accuracy for hidden prostate cancer?
NCT ID NCT07593079
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This study looks at whether taking bicalutamide for two weeks can make PSMA PET/CT scans better at finding small amounts of prostate cancer that standard scans might miss. It involves 20 men with recurrent prostate cancer and very low PSA levels. Participants are randomly assigned to have one scan or two scans (before and after bicalutamide) to compare detection rates.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A sharper eye on prostate cancer return: PSMA PET vs. MRI
- Can a new pill outsmart resistant prostate cancer?
- A second look: MRI screening may spot hidden prostate cancers